NASDAQ$LFCR
Lifecore Biomedical Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Lifecore Biomedical reported results for the second quarter of fiscal year 2023.
Lifecore Biomedical reported a decrease in consolidated revenues by 10.7% year-over-year, with a net loss from continuing operations of $12.4 million. The company also announced its intention to explore strategic alternatives to maximize value for stockholders.
- Consolidated revenues were $38.8 million, a decrease of 10.7% year-over-year.
- Consolidated gross profit was $7.1 million, a decrease of $7.6 million, or 51.7% year-over-year.
- Consolidated net loss from continuing operations was $12.4 million, including a non-cash intangibles impairment charge of $1.3 million and $4.1 million of restructuring and other non-recurring charges.
- Consolidated adjusted EBITDA was $(0.4) million, compared to $8.2 million in the prior year period.
Headline financials
Revenue & EPS history
Lifecore Biomedical · Revenue · Quarterly
$38.8M
Revenue by segment
Lifecore Biomedical · $24.3M total across 1 segment · Q4 2023
- CDMO Revenue$24.3M—100.0%
Forward guidance
Due to the Company's announcement of its intention to explore strategic alternatives, the Company is withdrawing its previously announced full year fiscal 2023 guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-2.1%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-0.4%
Avg return
30 days after
40%
25 / 63 earnings
Positive
+19.5%
Q2 2013
Best reaction
-66.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -3.9% | -13.0% | +8.9% | |
| Q1 2026 | -0.1% | +7.5% | +12.5% | |
| Q4 2025 | -6.3% | -0.3% | -3.0% | |
| Q3 2025 | -22.3% | -8.5% | +7.0% | |
| Q1 2025 | +8.1% | -3.6% | +24.8% | |
| Q4 2024 | -21.0% | -27.0% | -21.0% | |
| Q3 2024 | +8.2% | +15.7% | -5.0% | |
| Q2 2024 | +8.2% | +15.7% | -5.0% | |
| Q1 2024 | +8.2% | +15.7% | -5.0% | |
| Q4 2023 | -13.2% | -13.7% | -16.8% | |
| Q3 2023 | -0.5% | +3.8% | +18.1% | |
| Q2 2023 | -66.7% | -35.1% | -23.6% | |
| Q1 2023 | -5.3% | -5.4% | +4.0% | |
| Q4 2022 | +4.7% | +7.1% | -6.0% | |
| Q3 2022 | -8.3% | -9.6% | -20.8% | |
| Q2 2022 | -1.8% | -8.1% | -2.5% | |
| Q1 2022 | -9.6% | -10.4% | -4.7% | |
| Q4 2021 | -6.8% | -12.4% | -10.5% | |
| Q3 2021 | -10.4% | -10.0% | +12.0% | |
| Q2 2021 | -2.2% | -0.9% | -0.8% | |
| Q1 2021 | +1.2% | +0.8% | -2.7% | |
| Q4 2020 | -14.4% | -9.0% | -9.4% | |
| Q3 2020 | +15.3% | +15.6% | +31.6% | |
| Q2 2020 | -11.3% | -10.5% | -1.0% | |
| Q1 2020 | -3.6% | -6.1% | -9.4% | |
| Q4 2019 | +5.2% | -1.1% | +3.7% | |
| Q3 2019 | -9.3% | -17.5% | -18.7% | |
| Q2 2019 | -12.4% | -3.6% | +8.1% | |
| Q1 2019 | -0.2% | -4.1% | -2.5% | |
| Q4 2018 | -5.7% | -5.3% | -5.3% | |
| Q3 2018 | +6.5% | +3.4% | +1.9% | |
| Q2 2018 | +3.2% | +3.2% | +4.8% | |
| Q1 2018 | +11.3% | +8.4% | +9.6% | |
| Q4 2017 | -7.7% | -9.4% | -8.7% | |
| Q3 2017 | +10.1% | +19.7% | +16.0% | |
| Q2 2017 | -2.5% | -2.2% | -10.9% | |
| Q1 2017 | +5.6% | +5.3% | +4.4% | |
| Q4 2016 | +2.1% | +1.1% | +10.9% | |
| Q3 2016 | +0.5% | — | — | |
| Q2 2016 | -0.1% | — | — | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | -1.3% | — | — | |
| Q3 2015 | +1.2% | — | — | |
| Q2 2015 | -1.5% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | +5.0% | — | — | |
| Q3 2014 | -2.7% | — | — | |
| Q2 2014 | +1.1% | — | — | |
| Q1 2014 | -8.4% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q3 2013 | +4.0% | — | — | |
| Q2 2013 | +19.5% | — | — | |
| Q4 2010 | -1.7% | — | — | |
| Q1 2013 | -0.3% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q3 2012 | -0.5% | — | — | |
| Q2 2011 | -0.5% | — | — | |
| Q2 2012 | -0.5% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2010 | +5.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro